Baricitinib in Idiopathic Granulomatous Mastitis

Phase 2 Unknown 20 enrolled First Affiliated Hospital of Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

This study will explore the mechanism of targeted drug in treatment of idiopathic granulomatous mastitis, and clarify the clinical classification and corresponding markers.

Timeline

Start: 2023-05-04
Primary completion: 2025-04-30
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Baricitinib	Small molecule	2 mg	Oral

Baricitinib in Idiopathic Granulomatous Mastitis

Summary

Timeline

Drugs

Indications